|
|
||||||||
Ann Thorac Surg 2005;80:717-719
© 2005 The Society of Thoracic Surgeons
a Department of Surgery, Duke University Medical Center, Durham, North Carolina
b Department of Medicine, Duke University Medical Center, Durham, North Carolina
Accepted for publication February 10, 2004.
* Address reprint requests to Dr Milano, Department of Surgery, Box 3043, Duke Medical Center South, Durham, NC27710 (Email: milan002{at}mc.duke.edu).
Doxorubicin-induced cardiomyopathy is not uncommon and may progress to end-stage heart failure. Treatment of this condition with heart transplantation, however, requires that the primary malignancy be deemed "cured." We present the case of a 55- year-old woman who had doxorubicin-induced cardiomyopathy and non-Hodgkins lymphoma. The active status of her lymphoma precluded heart transplantation. She had end-stage heart failure and underwent the insertion of a left ventricular assist device as a destination therapy.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |